Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Clearly we have heavy sells with chart and various indicators now showing short term downward movement.
Never a good sign when a stock drops on heavier volume right around the time the deadline for an anticipated positive PR is due. People in the know usually find ways to buy or sell before news and often tip the direction a stock will go once news is released. So recent action is not a good omen.
The fact someone or someones have been purchases heavily and prevented the stock from rapid collapse may be a sign the news is delayed or positive results pushed out to the future, but not indefinitely. Curious is the fact that www.otcshortreport.com shows lower % of shares shorted on the higher sell volume, that's a somewhat positive possibly indicating catastrophic news is not pending, but only further short term delays?
Don't think we see a substantial announcement before end of Aug this week.
Post thought - this is time of month when larger holders dump shares they don't want showing up on month end listing reports, so somebody who accumulated BMSN in early August hoping for the homerun PR may be dumping now and buying next week.
AIMHO
If this were true, and BMSN resubmitted an updated IND for HemaXellerate on May 6th, then why are we in July (beyond the 30 day FDA response time) without final approval. There is clearly more to the "clarification" than what is being expressed below. In fact, in the official PR, it was stated that it should be approved because other "peers" are in support. In other words, there is a blockage that is not so simple because they didn't want to say what is was in the PR and there is no certainty as you express that it will be approved with or without more tests.
We know protocol and manufacturing has been given the green light, but when animal experiment safety tests do not get green light, it is not necessarily just paperwork to correct it as we are close to 2 months passing. Additionally, dCellVax, which was anticipated to file IND by end of March is now said to be expected in August, 5 months later. So everything is not smooth sailing.
WHAT WE DO NEED IS SIMPLY A THEORETICAL EXPANSION ON SAFETY DATA. They could take a text book and transcribe the information, it's that easy and simple at this point! It's merely an expansion on data so that the breaurocracy has its t's crossed and i's dotted for liability. It's beautiful, this implies that the FDA is GOING TO APPROVE THIS WITHOUT A REASONABLE DOUBT IN MY MIND.
ITS A VERY SMALL THING! IT IS ALSO VERY QUICK!
dmort545,
I can only hope that 49% of holders are institutions as that would be extremely significant, but the numbers reported below say only 216,979 shares outstanding when currently there are 2.9 billion.
According to Yahoo finance, 16% of shares are held by institutions and insiders with Koos owning 72 million, 60 million of which he purchased last Sept (a good sign he believes these INDs will come to some fruition).
Here is the breakdown from MarketClub.Feel free to request a Stock Trend Analysis Report
Year High 0.0091 Year High Date 2014-03-07
Year Low 0.0014 Year Low Date 2014-01-07
52wk High 0.0091 52wk High Date 2014-03-07
52wk Low 0.0011 52wk Low Date 2013-11-27
Year End Close 0.0016 Average Volume 18,128,951
Shares Outstanding 216,949 %Institutional 49.2
Liabilities 1.5M Beta 4.81
Volatility 108.37
Article I fear is old. Don't know where Feng Lin is...
While I fully support the efforts to research and find new events, we have to be careful. Website dates don't always reflect when the news came out and bloggers and websites rehash news.
It appears that the article on the Army research project and Dr. Feng Lin dates back at least to 2009 and is not recent news. Why haven't we been seeing Dr. Lin's name in any recent PRs, 10-Qs or FDA docs? Because I don't think he is actively working on this anymore for ENTB. Here's a link to the same article reported by Reuters in 2009: http://www.reuters.com/article/2009/05/13/idUS172921+13-May-2009+PRN20090513
So, I think we are still focused on Regen ticker, dCellVax submittal and Hema I "clarification".
...new in the pipeline for ENTB/BMSN... this is why that company recently bought 125 Mill. shares and why Koos bought the AAA shares to prevent a hostile take over... and the clinical trials... think about it people. Dr. Feng Lin...
http://www.stem-cells-news.com/1/adipose-derived-stem-cells-could-help-traumatic-brain-injury-patients/
Interesting that in order to reply, you completely changed the subject. Your post was that ENTB was recentely diluted with more shares and that was dragging down BMSN value.
I replied to that with the calculation of the impact of ENTB's dilution. You say I am wrong. Please point out how my calculation of ENTB's recent dilution is wrong instead of saying I'm wrong and switching the subject from ENTB to BMSN dilution.
If you want to talk about BMSN dilution, then we can change the subject and talk about it, but don't say I'm wrong on ENTB by going back over a year to BMSN dilution.
~ BMSN = Unfortunately your Calculations are far..from..Correct...frown When Koos Dilutes to the Toxic Financiers,, the Toxic Financiers make a HUGE % of the $$ off the Dilution & BMSN gets the crumbs... frown
Here is Some of the 2013 Dilutions & an interesting read on how "Dr. Dilutions." works... frown
-------
PS...
On the Run to .0165, BMSN had around 900Million Shares,, but now...2,000,000,000++shares (that is 2++ BILLION) have added "Weight" and the BMSN "Rocket" Can't lift off! frown
000's coming SOOON! frown
BMSN = 0.0030, no change. But if you reply to a posted message, please reply to content of the message, which is that in 20-30 trading days a lot can happen. BMSN could be at .0001 or lower or it could be at .02 or higher depending on news or no news.
~ BMSN = 0.0028 -0.0002 (-6.67%) LOD!! frown..so..farRr!..frown
Wow, Jack! Amazing.
Significant news. Let's see, how many shares were diluted?
1,998,000,000 shares at .0005 gives ENTB a total share value of $999,000. That means for every 1Million shares of dilution there is a .0005 per cent dilution of stock or (.0005 x $999,000) $500 impact on ENTB value.
How many shares did ENTB dilute? Must have BMSN running to the bank, oh my!
Well, 20-30 days of trading is a lot of trading days for a chart to change. If we are talking charts, then besides the recent fall of highs on lowering volume, one must point out higher lows on your chart moving L to R and also some positive divergence in the MACD which is more an indicator of consolidation before a move up rather than a future break lower.
But in 20-30 trading days, a lot can happen.
Frankly, today's low volume thus far is more a positive than a negative as volume shrunk significantly 3-4 days before the last PR release. When MMs that are playing the stock and short selling and rebuying stop or slow their activity, it often means news of some sort is approaching.
AIMO
The right side of the chart is where the stock is currently, and off the right side is where its heading.
BMSN share price is trading around the 200DMA and you can see the 50DMA moving down towards the current trading range.
Chances of the death cross forming within the next 20-30 days: very high.
What "sign" do you look for to know that news is coming?
How do YOU know if or when news is coming?
BMSN YEP and is it not good news there no FDA APPROVAL 10q bad report and no sign of any more news coming and that means down we go.
Are you thinking of March 6th submission as May?
PR reveals that they submitted data to FDA on March 6th (same day as PR for Regen dividend by the way it turns out) and then submitted modified IND on May 9th.
So, if FDA responded to data within 30 day framework or 1st week of April, then Regen took about a month for "clarification" or modified IND on May 9th (per FDA request).
Could be someone's typewriter was broken or they had more important things to do which caused the "simple clarification" to be delayed a month.
Wouldn't want to "speculate" on these facts per some posters, but it did take more than a day.
Yes, nothing is a sure thing. What is promising and encouraging for HemaXellerate I believe is the fact that it originates from cells of the patient itself and doesn't need to attack if I recall correctly, but just stimulate blood cell growth, so the circumstances experienced by this girl highlight the more problematic development of dCellVax rather than HemaXellerate in my non professional view.
I still have high hopes for HemaXellerate and the wide usage (market) it could immediately address. If this were in the hands of a Novartis, we'd be in trials I believe, but a 1-2 man show takes a lot longer to get there. So I'm not a pumper waiting for this to go to the moon every day. I'm heavily invested and hoping that the process is indeed going forward without an insurmountable wall in front and that eventually we will get green light for some type of trial, and if so, the value of the stock should greatly increase and start to hold more value as well.
I'm beyond thinking this is just another scam or false Koos dream. He may be a bit shady or not in his past dealings, but the science and involvement of Ichim and Min give me hope for eventual success of at least trials.
Let's hope it is not. For some reason I have the feeling it's more than just a couple of pages of written explanation since the PR did not give wording or sense of anticipated immediate approval upon "having clarified the issues at hand" or some similar indicator.
Drog_68, we didn't see higher volume because the news was not 100% green light and big money will not enter for steady uphill climb until full approval in my opinion.
HemaXellerate IND was filed over a year ago (Feb 2013) and with a small company like BMSN, the process takes time and is demanding. Larger investors aren't going to put 100s of thousands of investor dollars into a IND filing, but they might when FDA gives clinical approval and the pre-tests are very promising along with certain orphan drug status.
So for now, we bob up and down with the waves of emotion and speculation on each piece of news, knowing the steady current is not yet here.
GM,
PR only says a modified IND per FDA requests was submitted on May 9th. The good news is that Regen and FDA are working and going forward to this point which gives us hope for final approval, but PR does not, for reasons only they know, give us clarity as to what the nature of the modifications are to the IND. Does not say that they submitted responses or further data, only that a modified IND was submitted which I found curious. And the fact that Ichim's quote refers to general sense of medical community seeing promise and wanting these types of treatment to go forward rather than specifying what the issue was about the safety and how they were to address it.
You are right, we are back in a 30 day window it seems for FDA to respond to modified IND it seems, but my gut says that the IND is much narrower and the safety issue for broad Hemaxellerate usage may take more time.
I'm going to say no more studies as the new information has already been submitted on May 9th.
My two cents on Hemaxellerate Update.
What does the PR say in my personal opinion - for those wanting an objective take, here goes.
1. Regen submitted their complete response to FDA's ongoing inquiries dating back to Feb 2013 IND on March 6, 2014, hoping for complete and final approval. They adjusted their protocol per FDA directives most likely, they filled in details to assure manufacturing compliance and submitted the data from the animal experiments that the FDA had previously requested for both effectiveness and safety.
2.Trial protocol accepted, manufacturing accepted, "clarification on animal safety studies" needed.
My guess from wording of Ichim's response quoted in PR, I don't doubt that the studies showed effectiveness. The question is in the safety. While these treatments look fantastically promising, the long term effects of changing cell structures that will then reproduce in the body over a long period of time is unknown. Once the cells accomplish the immediate task they were designed for, it's uncertain (because this is still a new field) what the long term effects will be.
Much will depend not on the studies of Regen, but on the FDA's attitude, I think, towards these new types of treatments.
On the positive, aplastic anemia is a fatal condition in most cases, so for Regen and FDA, there is a strong impetus to allow the clinical trials I would think since you are dealing with people who otherwise will die in a short period of time. Safety? What would be worse for these patients than imminent death?
On the possibly negative side, the FDA might not want to give green light and create a precedence for allowing other types of stem cell treatments for non fatal conditions where the outcome is unknown.
From the slow and careful reading of the words and responses in the PR, my gut says this won't be resolved in a couple of days, but may be looking as several weeks and/or further studies.
PR portion I'm referring to is below.
The May 9th resubmission to FDA made by Regen is unclear as to whether it addressed the safety issues or not in my mind as they merely stated that they submitted a modified IND.
What those modifications are, we don't know. Could be to narrow the scope of the trials to a narrower market as a result of safety questions? maybe.
This is the Hemaxellerate side, which seems delayed for a while. As to what is happening with dCellVax, we still do not know which does not give me a good feeling since it was to have been addressed as an IND before end of March and here we are mid-May without any word.
Could come tomorrow (good or bad). Could be kept secret until they get 1st round of Questions from FDA and have time to respond, we simply do not know what is going on.
On March 6, 2014, Regen submitted a protocol modification, additional details on manufacturing, and new data to the FDA regarding therapeutic effects of HemaXellerate Iâ„¢ in animal models of diseases similar to aplastic anemia in humans, as well as additional safety data.
The Company reports the FDA accepted the clinical protocol and the product manufacturing information provided, however, clarification on animal safety studies was requested.
"Given the HemaXellerate Iâ„¢ product is derived from the patient's own fat tissue, and numerous key opinion leaders support clinical entry of our product, as demonstrated by our peer reviewed publication http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf., we are confident the safety studies the FDA requested clarification on can be addressed in a timely fashion," stated Thomas Ichim, Regen's Chief Scientific Officer and Board Member.
"The role of the FDA is to ensure the highest standards of safety for new products. We view the requested clarifications from the FDA in regards to safety studies as part of the normal process of FDA submission. Given that the HemaXellerate Iâ„¢ possesses the potential to treat multiple conditions, we view the demonstration of safety as a fundamental step, which will position the Company to expand use of this 'stem cell drug' for multiple other indications," noted David Koos, the Company's Chairman & CEO. "Having passed the clinical trial protocol approval and the manufacturing approval, are major milestones for Regen."
On May 9, 2014 the Company updated its IND with changes requested by the FDA and submitted them for review.
HOWEVER, a response to the animal studies data was submitted on May 9, 2014 (check out the short report for May 9, 2014 at www.otcshortreport.com for BMSN. Interesting, No?
No doubt, today's PR is a mix, but the hopeful news is that they responded last Friday in a way that satisfies. It's still a toss up, but the fact the new clinical trial protocol is APPROVED and manufacturing is APPROVED, then we are only one step from full approval and clinical trials and according to previous email on animal clinical trials, the results were very positive. No doubt, there are other bigger boys in the stem cell field with FDA connections that might even want to slow BMSN research down for their own monetary gain, but I am encouraged that BMSN/REGEN filed patents back on 3/6/2014 for some of their new work.
More positive than negative today and the fact that the PR was released right after IND resubmission and didn't wait for FDA response may be significant (relating to REGEN itself?).
Don't know. AIMO.
Please, just facts and not personal speculation. Unless you are making other people's trades for them, 1) How do you know who is buying and who is selling and 2) How do you know that "NO NEWS" is coming. Are you revealing insider information?
This board should relay company developments, DD and deductions based on those indicators, not clairvoyant predictions.
While you can have the opinion it's not going anywhere, how can you say "WITH NO NEWS COMING"?
That doesn't seem objective at all. There is a slew of possible news coming:
Patent filing of 11/13/13 - response?
Regen ticker symbol news
HemaXellerate experiments news and NDA response filing
dCellVax experiment news and NDA filing.
I don't know when news is coming, but news (good or bad) is definitely coming, so how could you possibly make the statement you just did and have 143 followers?
Traz,
Previously, it was stated that 10Q would have to give disclosure of activities relating to test trials and FDA response and/or filings.
How is it, then that the REGEN 10Q doesn't mention them AT ALL. The previous PR stated that before end of Quarter March 31st, they would both file FDA response for HemaXellerate I and dCellVax.
This 10Q covers that period without any mention, so now I'm at a loss at to what to believe since it was previously posted here that a 10Q has to reveal information that might not otherwise be revealed.
Quiet period linked to IPO of Regen.
According to this article, the quiet period is related to the initial public offering of a stock. With REGEN filing for ticker symbol and therefore initial public trading, the quiet period will extend I believe until Regen begins trading which is dependent on ticker symbol and MM submission and therefore we don't know the date or "days" left.
Since Koos is mainly a one man show trying to tie all these things together, it may take longer than normal, but when or how long is unknown to everyone unless there is someone with insider information and therefore anyone who "claims" to know and give specifics is either committing a possible crime or full of nonsense.
http://www.goingpublicinformation.com/Selling_Stock_Getting_Ticker_Symbol.htm
We wait.
As Traz has pointed out, if they had bad news on the trials before filing for spin off etc., they would be obligated to report. If they had negative results in the trials, why spend all the extra effort to spinoff REGEN and have IPO only to have to go public with news of failure while launching an IPO. Who would that draw to invest?
So while we have silence, there is reason to deduce that the silence is most likely tied up with good news to come.
IMO
Since there isn't any company news to read, how about some educational SEC and FINRA reading. No, it's not as colorful as bashing or pumping, but I did find it informative and most likely applicable to understanding current BMSN/REGEN situation:
http://www.goingpublicinformation.com/Selling_Stock_Getting_Ticker_Symbol.htm
With S1 filing, Prospectus and Spin-off, my personal reading of the Understanding Securities Laws article tells me that BMSN entered into an imposed silent period until FINRA and IPO approval (or outright rejection).
So, you can pick your own current situation interpretation:
1. Basher: The BMSN/REGEN spin off was a total smoke screen for a failed product that never will come to FDA approval for human trials (a head scratcher and a lot of work to just delay the inevitable public failure and open yourself to a bunch of law suits)
2. Pumper: Koos has multiple big pharma companies begging him to buy out the potential of the animal trials and once this get a FINRA symbol, it will never stop going up. (Fantasy dreaming)
3. DD: Koos believes the data from trials will be enough to get FDA approval and therefore did the REGEN spin-off to upgrade the value of his own shares and fulfill SEC and FINRA requirements for a new stock and public trading with a share base not so easily manipulated and the current silence is due to parameters of SEC law, which does not assure FDA human trial approval of either HemaXellerate I nor dCellVax, but does get a basis of belief that things are going forward and when/if REGEN gets Stock ticker symbol, some significant news is likely to follow.
To each his own...
Those who assure one side or the other may very well have their own personal reasons of trying to sway others.
To the rest, thank you for sharing the objective research you've come across and sharing on the company and developments to help each person make their own decisions on information and not fantasy.
Actually the volume levels are a semi-positive that the bleeding may nearly be over. Since the price has been falling, the fact that negative volume has nearly dried up is a good thing, not a bad sign. If negative trading volume were increasing here, then it would be a sign to bail.
The fact that negative volume is much lower the past 2 days might be a sign to buy, not to sell.
For those who seek to understand the process. Please sticky as a reference point for those of us who are not SEC experts and who are trying to understand the process of what is happening and why or why not things are not happening rapid fire. I am one of those people and came across this article which I wish I had read 3 weeks ago. (Filing of S1, getting SEC approval and then a ticker symbol from FINRA is not a simple form or process. It takes time for all and there are related "quiet periods", of which I am now personally convinced that BMSN is in until REGEN gets approved ticker symbol from FINRA and begins trading. No time frame for that is certain or known. See link below for an informative article.
http://www.goingpublicinformation.com/Selling_Stock_Getting_Ticker_Symbol.htm
New4This, has anyone commented or addressed the links you posted? Seems like a direct competitor to HemaXellerate I IND and orphan status.
I'm not sure what the "Designated as safety issue: Yes" means, but this is a study that has already completed Phase I trial in Brazil parallel to what BMSN is trying to do. BIG question: is our lack of news from Koos related?
Well, that would be my last hope that positive news is actually going to come out. Although the divy shares of Regen are a dividend "spin-off", the fact still remains that Regen is not a publicly traded company and if/when it gets a ticker and market to trade on, that many be combined with a yet to be revealed IPO of shares as well. But even not, wouldn't the fact that it would be REGEN's initial public debut as a publicly traded company trigger the IPO quiet period mentioned here:
http://www.investopedia.com/terms/q/quietperiod.asp
I still think they have to be quite for IPO purposes...I know people have said the quite period does not apply
The good news is that there isn't any bad news yet, but the bad news is that the good news expected hasn't arrived.
We are in stagnant waters until the truth of what has been going on with experiments and FDA is revealed and since both success or failure is a "material event" in my opinion, there is no excuse for a legitimate company to withhold it. Oh, I realize there can be a bucket of reasons, but shareholders should be updated within time frames that are given in official company PRs and that meant the end of March.
IMO
Best to go and read a few company PRs to know what is happening since there are not many, won't take you long. Yahoo finance search BMSN and read the Nov/Dec 2013 PRs and you will know the timeframes.
Time frame is for BMSN submittal of response to FDA regarding HemaXellerate I IND of Feb 2013 and initial IND submission to FDA for dCellVax. Cannot say when FDA will give their decision or response and we did not know FDA's response for initial filings for weeks after Koos had them.
Scottrade REGB#9; TDA - no symbol. Don't know for sure what REGB#9 means.
Ok. I must have missed earlier posts. Can't live to read all the posts. Just finished work and checking to see if anything major has hit. I can only dream of selling BMSN at .50 Wouldn't have to work anymore if that were the case, which I wouldn't mind. I'd be more than happy with .05. Have been holding most of my shares for over a year.
GLTY
Don't understand why posting chart? Bid is at .01 or less. What does it matter that someone is selling at .50?
SCOTTRADE ACCT SHOWS DIVY SHARES: Regen divy shares are now showing in my Scottrade account. TDA account earlier today, so other Scottraders should have theirs by morning as well I would think.
A good PR tomorrow would make my day or it could make my retirement. Let's hope this divy Spin off is truly a sign of the success to come. 'Til morning, over and out.
Have to ask Koos. If restructuring brings float down, stops MM manipulation and puts REGEN on NASDAQ instead of OTCQB, then the obvious answer is "Yes", it's a good thing all else being equal.
What the focus should be is not on figuring out value of shares that don't yet have a market or evaluation, is whether we get a positive PR confirming the science of the testing for the FDA response and IND. If neither materializes, it doesn't matter how many shares or where there are, they won't have value. If BMSN files successful FDA for HemaXellerate I and dCellVax gets an IND, then value of BMSN and REGEN will rise precipitously and you don't have to worry about what is spin-off, restructuring or bonus.
Let's keep a focus and share DD and real news to help all here.
Traz, I thought you needed to wait to file for Orphan Drug status after FDA approval. If so, I don't see how BMSN could announce both at once.
So the question remains, has BMSN submitted the findings of the HemaXellerate experiments to satisfy the FDA or not?
Could he have determined the experiments didn't provide enough data afterall and be starting a new experiment time period and need to tell us within 3 days or could he withhold that info.
The fact we haven't even heard of the submital of the test results or anything about the test results since Dec 11th for a company needing investors and momentum and money for trial clinics doesn't make sense to me if the results were positive and the filing occured, which is what is making me nervous on this. But I'll wait for the 31st and continue to hope.
Did get divy shares in TDA today, still waiting on Scottrade.
If everything was up and up, yes, but many don't play by the rules or trade it via outside "shell company" facades or "friends". Insider trading happens all the time. Not saying Koos has, but the fact that BMSN has walked down steadily after quick rise to .0091, all the time with the potential PR to send this over a penny doesn't make sense unless some people knew a PR wouldn't be forthcoming. News about 2 major developmental events were promised by the end of March, so after the rise, no one could sell without the threat of this "skyrocketing higher" on any pending news and yet we've seen steady, calculated sell-off, not a quick drop.
Doesn't give me a good feeling at all.
AIMO
Trucker Joe, are you still out there? Looks like nearing prime time for you to load. Wish I had unloaded at .009 and bought back at divy time.
Now all I can do is wait and hope that Koos didn't drive this up only to short it down for more money before a crash on bad news.
With d5wr59mfi8's DD post, BMSN will not have to comply with new requirements until end of its fiscal year, so plenty of time for FDA approval and IND to bring it over a penny. Without that, I would see Koos doing a reverse split of BMSN stock to get the price over a penny in order to stay on OTCQB. All in theory, but none of that will matter if HemaXellerate gets FDA clinical green light as Orphan Drug status will follow in about 30-45 days and BMSN and Regen share value will be MUCH higher.
Until we know whether FDA gives thumbs up or thumbs down, BMSN will wander.
Thanks. That clears the issue and give BMSN more time for sure to remain on OTCQB as it is already reporting compliant and with the recent S1 filings, had to put everything out into the open.
All we need for pennyland is a solid PR that confirms the experiments for HemaXellerate have met FDA approval. While dCellVax IND will also boost price temporarily, it's uncertain for how long as it can face the same delays the HemaXellerate I filing did while a HemaXellerate Green light from FDA will keep both BMSN and REGEN on people's charts.
IMO
NASDAQ has a $1.00 price rule. Markets create their rules for listing and reporting, so as per the article, the OTC Market is creating new rules for the OTCQB portion of the OTC markets. There is more than one OTC market.
See the link to OTC markets and you can read some more: http://www.otcmarkets.com/home Click on the Marketplaces tab for more information.
Being delisted from a market doesn't mean all trading on the company ceases, it will just trade on a different market. However that can affect who invests and how easy it is to get exposure etc.
There is another requirement you must consider in the article:
"The bid requirement, in which stocks must have been quoted for at least 1 cent daily over a 30-day period or be dropped from the market, aims to ferret out companies that fall prey to dilutive stock fraud schemes and promotions, OTC Markets said."
This will need clarification by the rule enforcers, but it states "must have been" meaning an already completed action, verses "will need to". My reading of this is that as of May 1st, any stock currently listed on the OTCQB will need to have a 30 day over a penny price history in place to continue on the market or it not meet market requirements. It cannot hit a penny on May 1st and meet the 30-day period. That is why I stated that we need positive news by end of March to send this over a penny and stay for a 30 day period in order to meet the May 1st deadline.
Otherwise, BMSN would need to file for an exemption to the rule.
In any case, if we don't get a positive PR soon, this won't be anywhere near a penny and if we get bad news, it will revert to .000s
NO...May 1st begins the new minimum one-cent bid price requirement, per the article you quote. Therefore the one-penny price requirement should be obtained by then. However it does NOT necessitate a PR being released by March 31st... although THAT would be very nice!